← Leaderboards
David E Sterner
Progenra, Inc.
$7,582,782
Attributed
$7,582,782
Total exposure
14
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.2M · FY2005–21$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$7,582,782 · 14
By mechanism
R44$4,877,938 · 4
R43$2,704,844 · 10
Top collaborators
No co-investigators on record.
Most similar at Progenra, Inc.
Same institution · by research overlap
- Michael R Mattern$5,800,503
- Benjamin Nicholson$1,181,002
- Seth Goldenberg$265,823
- Kumar Suresh$5,007,499
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseMulticatalytic Endopeptidase ComplexHigh Throughput ScreeningInhibitor/AntagonistProteinsUbiquitinCellsDrug DiscoveryPathway InteractionsUbiquitin-Protein LigasePharmaceutical PreparationsLeadEnzymesIn VitroInterestPharmaceutical ChemistryPre-ClinicalProtein DegradationSmall MoleculeTherapeutic AgentsPreventPharmacologic SubstanceAmericanLigase
Grant awards (18)
Novel TXNIP degraders for treating diabetes$265,978
R43 · FY2021 · DK · contact PI
Nonalcoholic Steatohepatitis Therapies from the Ubiquitin Pathway$224,618
R43 · FY2019 · DK · contact PI
A novel mechanism based therapy for cystic fibrosis$204,995
R43 · FY2016 · HL · contact PI
Novel molecular therapeutics for cystic fibrosis$667,073
R44 · FY2015 · HL · contact PI
Selective inhibitors of ubiquitin E3 ligase to treat high cholesterol$611,663
R44 · FY2015 · ES · contact PI
Ubiquitin E3 ligase detection by fluorescence resonance transfer$611,190
R44 · FY2015 · GM · contact PI
Ubiquitin E3 ligase detection by fluorescence resonance transfer$723,331
R44 · FY2014 · GM · contact PI
Novel molecular therapeutics for cystic fibrosis$668,380
R44 · FY2014 · HL · contact PI
Selective inhibitors of ubiquitin E3 ligase to treat high cholesterol$611,663
R44 · FY2014 · ES · contact PI
Ubiquitin based therapy of aggressive cancer cell populations$224,768
R43 · FY2014 · CA · contact PI
Novel molecular therapeutics for cystic fibrosis$282,804
R43 · FY2012 · HL · contact PI
Molecular screen for isopeptidase inhibitors to treat pulmonary disease$467,549
R44 · FY2011 · HL · contact PI
Selective inhibitors of ubiquitin E3 ligase to treat high cholesterol$296,751
R43 · FY2011 · HL · contact PI
Molecular screen for isopeptidase inhibitors to treat pulmonary disease$517,089
R44 · FY2010 · HL · contact PI
Functional assays for osteoporosis therapeutics$293,745
R43 · FY2008 · AG · contact PI
Molecular screen for isopeptidase inhibitors to treat pulmonary disease$269,268
R43 · FY2007 · HL · contact PI
Ubiquitin ligase as a therapeutic target for arthritis$278,569
R43 · FY2006 · AR · contact PI
Molecular Screens for Deubiquitinase Function$363,348
R43 · FY2005 · DK